With COVID-19 transitioning from acute pandemic emergency to endemic respiratory threat, the question of who truly benefits from antiviral treatment remains clinically consequential — particularly for older adults and immunocompromised individuals who still face disproportionate risk of severe disease and hospitalization.
This correspondence published in the New England Journal of Medicine revisits the evidence base for nirmatrelvir–ritonavir (Paxlovid) in higher-risk outpatient populations. The original EPIC-HR trial demonstrated a roughly 89% relative risk reduction in hospitalization or death among unvaccinated, high-risk adults treated within three days of symptom onset. However, subsequent real-world data and follow-up studies have produced more heterogeneous results, with effect sizes often considerably smaller in vaccinated cohorts or those infected with newer Omicron subvariants. This correspondence appears to contribute updated analysis or commentary bearing on the treatment's benefit profile in the current epidemiological context, though the excerpt does not permit full quantitative characterization.
The broader evidentiary picture surrounding Paxlovid has grown more complex since its emergency authorization. Multiple observational studies in vaccinated populations reported attenuated or statistically non-significant benefits, raising questions about patient selection and timing. The drug's significant interaction profile via ritonavir's CYP3A4 inhibition also complicates prescribing in the very populations — older, multi-morbid adults on polypharmacy — who stand to benefit most. The phenomenon of COVID rebound following treatment completion has further muddied clinical interpretation. As a NEJM correspondence rather than a primary trial, this piece likely offers important critical appraisal or new data framing, making it valuable for clinicians navigating treatment decisions in a landscape of waning immunity and variant evolution. Given the journal's stature and the clinical stakes for vulnerable populations, the analysis merits close attention from practitioners and evidence-watchers alike.